Modality
Vaccine
MOA
KRASG12Ci
Target
CGRP
Pathway
Innate Imm
Endometrial CaGBMCF
Development Pipeline
Preclinical
~Nov 2015
→ ~Feb 2017
Phase 1
~May 2017
→ ~Aug 2018
Phase 2
Nov 2018
→ May 2031
Phase 2Current
NCT04290579
423 pts·Endometrial Ca
2023-02→2031-05·Completed
NCT07215029
1,255 pts·CF
2018-11→2030-05·Not yet recruiting
1,678 total pts2 indications
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2030-05-254.2y awayPh3 Readout· CF
2031-05-275.2y awayPh3 Readout· Endometrial Ca
Trial Timeline
Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3
P2/3
Not yet…
P2/3
Complet…
Catalysts
Ph3 Readout
2030-05-25 · 4.2y away
CF
Ph3 Readout
2031-05-27 · 5.2y away
Endometrial Ca
CompletedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04290579 | Phase 2/3 | Endometrial Ca | Completed | 423 | Biomarker |
| NCT07215029 | Phase 2/3 | CF | Not yet recr... | 1255 | eGFR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Lisolucimab | Novartis | Approved | CD20 | |
| Gozelemzoparlimab | Merck & Co | Phase 2 | FXIa | |
| AZN-8478 | AstraZeneca | NDA/BLA | SHP2 | |
| Pexazasiran | Sanofi | Preclinical | FXIa | |
| Terasacituzumab | Novo Nordisk | NDA/BLA | IL-23 | |
| TAK-9344 | Takeda | Phase 3 | CGRP | |
| Zenotinib | BioNTech | Phase 1 | CGRP | |
| Capiglumide | BioNTech | Preclinical | CGRP | |
| BII-4342 | Biogen | Phase 2/3 | CGRP | |
| ALN-6288 | Alnylam | Approved | LAG-3 |